Study S000856

Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07244003
Acronym: MESSAGE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 430
Start: 2025-03-29
Primary completion: 2027-12-31
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: DRUG:Metformin; DRUG:Triple Therapy of Other Oral Antidiabetic Drugs; DRUG:ganagliflozin; DRUG:liraglutide
Results posted: FALSE

Registered primary outcomes

The change of HbA1c compared to the baseline [from baseline to week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.